Again, the majority of high-risk patients did not receive RAI, with only 41% of high-risk patients receiving RAI.Ĭonclusions: MSO is a rare malignancy with apparently variable and inconsistent patterns of postoperative RAI administration. In our subsequent analysis using the SEER registry, there were 95 MSO patients, and 18 received RAI. High-risk stratification was associated with decreased OS via univariate Cox regression (hazard ratio = 4.0, p = 0.034). Twenty-one NCDB patients were stratified as high risk, and 30% of high-risk patients received RAI. RAI therapy was associated with distant metastasis ( p = 0.005) and lymph node status ( p = 0.012). Rasa Zarnegar contributions have acclaimed recognition from honourable subject experts around the world. Rasa Zarnegar has authored I145and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Results: In the NCDB analysis, a total of 158 patients were identified, and 19 received RAI. Rasa Zarnegar is currently providing services as professor. We then queried the Surveillance, Epidemiology, and End Results (SEER) 18 registry for patients with MSO between 20 to confirm our risk stratification analysis. Risk stratification, demographic, oncological, and clinicopathologic data were compared between the groups receiving and not receiving RAI therapy. We stratified patients into low-, intermediate-, and high-risk groups using metastasis, extraovarian extension, lymphovascular invasion, lymph node status, surgical margins, tumor size, and grade. We adapted the 2015 American Thyroid Association risk guidelines for MSO patients. Kaplan–Meier curves were used to estimate overall survival (OS), and variables associated with OS were assessed via univariate Cox regression. Demographic, oncological, and clinicopathologic data were compared between groups using Fisher's exact test. Methods: The National Cancer Database (NCDB) was queried for patients with MSO between 20. In this study, we aimed to propose a risk stratification and analyze RAI utilization patterns in MSO cases. While surgical excision of the primary tumor is widely accepted as standard of care, recommendations for adjuvant treatment of MSO-whether or not to administer radioactive iodine (RAI)-are based largely on case reports and remain debated. Specialists Cardiologists Chiropractors Dermatologists ENT Doctors Eye Doctors Family Doctors. Introduction: Malignant struma ovarii (MSO) is a rare thyroid cancer arising within an ovarian teratoma. Directions to 520 East 70th Street Starr 8, New York, NY 10021 - Rasa Zarnegar.